Table 1.

Baseline characteristics of the study cohort

Characteristic	Low dose ≤12.5 mg [n = 63]	High dose >12.5 mg [n = 159]	p-value
Female, n [%]	29 [46.0]	76 [47.8]	0.812
Age, mean [SD]	35.0 ± 14.0	38.1 ± 13.9	0.125
IBD type			0.802
Crohn’s disease, n [%]	47 [74.6]	116 [73.0]
Ulcerative colitis, n [%]	16 [25.4]	43 [27.0]
Disease duration, mean [SD]	10.7 ± 9.6	10.4 ± 9.4	0.802
Smoking			0.021
Never, n [%]	53 [86.9]	106 [68.4]
Former, n [%]	5 [8.2]	32 [20.7]
Current, n [%]	3 [4.9]	17 [11.0]
Disease location			0.894
CD ileitis, n [%]	6 [9.5]	12 [7.8]
CD ileocolitis, n [%]	27 [42.9]	68 [44.4]
CD colitis, n [%]	15 [23.8]	32 [20.9]
UC proctitis, n [%]	2 [3.2]	2 [1.3]
UC left-sided colitis, n [%]	3 [4.8]	8 [5.2]
UC pancolitis, n [%]	10 [15.9]	31 [20.3]
Perianal disease	14 [22.2]	49 [31.4]	0.174
Stricturing	14 [22.2]	35 [22.4]	0.973
Penetrating	21 [33.3]	59 [37.8]	0.532
Stoma	2 [3.2]	13 [8.4]	0.168
Pouch	8 [12.7]	5 [3.2]	0.007
Past history
Prior anti-TNF, n [%]	45 [71.4]	123 [77.4]	0.353
Prior surgery, n [%]	16 [25.4]	48 [30.8]	0.429
CRP mg/L, mean [SD]	14.1 ± 27.8	19.8 ± 28.6	0.209
Albumin g/dL, mean [SD]	4.2 ± 0.5	4.0 ± 0.5	0.116
Started MTX within 90 days of anti-TNF, n [%]	34 [54.0]	104 [65.4]	0.113
Route of MTX administration n [%]			<0.001
Oral administration	61 [96.8]	62 [39.0]
Injection	2 [3.2]	97 [61.0]
Anti-TNF agent			0.412
Infliximab, n [%]	24 [38.1]	60 [37.7]
Adalimumab, n [%]	28 [44.4]	65 [40.9]
Certolizumab, n [%]	6 [9.5]	27 [17.0]
Simponi, n [%]	5 [7.9]	7 [4.4]